Prelude Therapeutics Inc Forecast, price target & analysts
Prelude Therapeutics Inc Target price 2024 - Analyst rating & recommendation
Prelude Therapeutics Inc Classifications & Recommendation:
Prelude Therapeutics Inc Price Target
| Target Price | $3.33 |
| Price | $1.21 |
| Potential |
175.48%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Prelude Therapeutics Inc 2025 .
The average Prelude Therapeutics Inc target price is $3.33.
This is
175.48%
register free of charge
$5.00
313.22%
register free of charge
$1.00
17.36%
register free of charge
|
|
| A rating was issued by 4 analysts: 2 Analysts recommend Prelude Therapeutics Inc to buy, 0 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Prelude Therapeutics Inc stock has an average upside potential 2025 of
175.48%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.00 | 2.00 |
3 Analysts have issued a sales forecast Prelude Therapeutics Inc 2024 . The average Prelude Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
Revenue Estimates
| 2023 | $0.0 | |
|---|---|---|
| 2025 |
$0.0
100.00%
Unlock
|
|
1 Analyst has issued an EBITDA forecast Prelude Therapeutics Inc 2024 . The average Prelude Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Margin
1 Analyst has issued a net profit forecast Prelude Therapeutics Inc 2024 . The average Prelude Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.02 | -1.77 |
| 17.21% | 12.38% | |
| P/E | negative | |
| EV/Sales | negative |
1 Analysts have issued a Prelude Therapeutics Inc forecast for earnings per share. The average Prelude Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Prelude Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | -20.58 | |
|---|---|---|
| 2024 |
-30.87
50.00%
Unlock
|
|
P/S ratio
| Current | ||
|---|---|---|
| 2024 |
36.88
50.00%
Unlock
|
|
Prelude Therapeutics Inc...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
